Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Decibel Therapeutics Inc.
Headquarters: Boston, MA, United States of America
Website: N/A
Year Founded: 2015
Status: Acquired
BioCentury | May 14, 2024
Product Development
Clinical Report: MacroGenics faces ADC safety concerns
Plus data from CytomX, Merck, Regeneron and more
BioCentury | Aug 10, 2023
Finance
Aug. 9 Quick Takes: Alltrna raises $109M for unified approach to stop codon diseases
Plus: Venture cash for ADARx, Georgiamune, Neurophth and updates from Regeneron-Decibel, Novartis, Sunbird-Glympse, Denali-Takeda and more
BioCentury | Nov 8, 2022
Management Tracks
BMS’ Rutstein joins Daiichi as head of oncology
Plus new CMO at Boehringer Ingelheim, and updates from Repertoire, Atsena, TAAV and more
BioCentury | Oct 18, 2022
Deals
Lilly buying otology company Akouos to add another gene therapy pipeline
As biotech nears first-in-human study for genetic hearing loss, pharma deepens commitment to modality via structured deal
BioCentury | Jun 15, 2022
Data Byte
Third Rock’s penchant for platforms, product engines
The firm has backed 11 companies since the start of 2021; none are single-asset plays
BioCentury | Nov 3, 2021
Finance
Shoreline draws $140M to advance cell therapy pipeline
Xanthopoulos-led company now has received $300M+ from equity rounds, partnerships
BioCentury | Aug 20, 2021
Management Tracks
Actelion takeout, COVID-19 vaccine among Gorsky’s J&J highlights as he readies to hand CEO job to Duato
Plus: BlueSphere, MAIA, Solid, Decibel, Corbus
BioCentury | Jun 10, 2021
Deals
BeiGene picks iPS cells for its move into cell therapies via Shoreline deal
BeiGene enters cell therapy via deal with San Diego iPS cell company for $45M up front
BioCentury | Jun 3, 2021
Management Tracks
Gilde builds public markets expertise with Muijrers hire; plus Nanobiotix, Shattuck, Ichnos, Generate, Alpine and more
Joep Muijrers has joined Gilde Healthcare to lead the Dutch firm’s venture and growth capital fund. Muijrers is a veteran of PureTech Health plc (LSE:PRTC; NASDAQ:PRTC), where he served as
Items per page:
1 - 10 of 40